PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme
Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival LA JOLLA, Calif. , Nov. 19, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of
View HTML
Toggle Summary Regulus Reports Third Quarter 2018 Financial Results and Recent Updates
$47 Million Restructured Sanofi Collaboration Executed Initiated New Chronic Mouse Toxicity Study for RGLS4326; Data Anticipated in Q1 2019 LA JOLLA, Calif. , Nov. 8, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and
View HTML
Toggle Summary Regulus Announces Successful Restructuring of Sanofi Collaboration
Sanofi Will Assume Development of RG-012 for Alport syndrome LA JOLLA, Calif. , Nov. 6, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has
View HTML
Toggle Summary Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018
LA JOLLA, Calif. , Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present data from ATHENA, its global natural history of disease
View HTML
Toggle Summary Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018
LA JOLLA, Calif. , Oct. 22, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical data regarding RGLS4326, a single stranded,
View HTML
Toggle Summary Regulus Regains Compliance with NASDAQ Listing Requirements
LA JOLLA, Calif. , Oct. 18, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it received notice from The Nasdaq Stock Market LLC "NASDAQ" indicating
View HTML
Toggle Summary Regulus Therapeutics Announces Reverse Stock Split
LA JOLLA, Calif. , Oct. 4, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that at the special meeting of stockholders, held September 28, 2018,
View HTML
Toggle Summary Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference
LA JOLLA, Calif. , Oct. 2, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference
LA JOLLA, Calif. , Sept. 27, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus Provides Pipeline Updates
Hepatitis B virus Lead Compound Demonstrates Compelling Data in Preclinical Studies Glioblastoma multiforme Lead Compound Demonstrates Significant Survival Benefit as Monotherapy and in Combination with Temozolomide in Preclinical Disease Models Improvement in Multiple Key Endpoints Observed in
View HTML